Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the ...

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with ...

The National Health Technology Assessment System (SiNATS) has contributed over the last decade to improving access to medicines, promoting the sustainability of the SNS and reducing waste, but ...

NANJING, China and GAITHERSBURG, Md., June 27, 2025 /PRNewswire/ -- TransThera Sciences Inc. ('TransThera') announced that the translational studies of tinengotinib in CCA with acquired resistance to ...

DelveInsight's Anti-CCR8 Antibodies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025; Marks the ...

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in ...